Helus Pharma’s Bold Depression Bet Faces Its Defining Test
Helus Pharma (NASDAQ:HELP) is approaching a crucial Q4 readout that could reshape the investment story. The company says its earlier depression data showed durable remission after only two doses, but Phase 3 is the real test. If the trial confirms the promise, investors may start looking at Helus very differently. Interview date: July 1, 2026. … Read more
